1
|
Gobbi PG, Ferreri AJ, Ponzoni M and Levis
A: Hodgkin lymphoma. Crit Rev Oncol Hematol. 85:216–237. 2013.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Cartwright R, Brincker H, Carli PM,
Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, de Sanjose S,
Tumino R and Vornanen M: The rise in incidence of lymphomas in
Europe 1985–1992. Eur J Cancer. 35:627–633. 1999. View Article : Google Scholar : PubMed/NCBI
|
3
|
Weber AL, Rahemtullah A and Ferry JA:
Hodgkin and non-Hodgkin lymphoma of the head and neck: Clinical,
pathologic and imaging evaluation. Neuroimaging Clin N Am.
13:371–392. 2003. View Article : Google Scholar : PubMed/NCBI
|
4
|
Dirim B, Karakas L, Oyar O, Bener S, Sener
M, Yagtu M, Erdogan N, Uluc E and Altay C: An unusual Hodgkin's
lymphoma case presenting with upper extremity multiple masses. Clin
Imaging. 36:873–876. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Travis WD, Banks PM and Reiman HM: Primary
extranodal soft tissue lymphoma of the extremities. Am J Surg
Pathol. 11:359–366. 1987. View Article : Google Scholar : PubMed/NCBI
|
6
|
Neskoromna-Jędrzejczak A, Tyndorf M,
Arkuszewski P and Kobos J: Head and neck lymphomas-diagnostic
difficulties. Pol Przegl Chir. 84:113–118. 2012.PubMed/NCBI
|
7
|
Kashyap R, Rai Mittal B, Manohar K,
Balasubramanian Harisankar CN, Bhattacharya A, Singh B, Malhotra P
and Varma S: Extranodal manifestations of lymphoma on
[18F]FDG-PET/CT: A pictorial essay. Cancer Imaging.
11:166–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Diehl V, Sextro M, Franklin J, Hansmann
ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van
Krieken J, et al: Clinical presentation, course, and prognostic
factors in lymphocyte-predominant Hodgkin's disease and
lymphocyte-rich classical Hodgkin's disease: Report from the
European Task Force on Lymphoma project on lymphocyte-predominant
Hodgkin's disease. J Clin Oncol. 17:776–783. 1999.PubMed/NCBI
|
9
|
Guermazi A, Brice P, de Kerviler EE, Fermé
C, Hennequin C, Meignin V and Frija J: Extranodal Hodgkin disease:
Spectrum of disease. Radiographics. 21:161–179. 2001. View Article : Google Scholar : PubMed/NCBI
|
10
|
Ilica AT, Kocacelebi K, Savas R and Ayan
A: Imaging of extranodal lymphoma with PET/CT. Clin Nucl Med.
36:e127–e138. 2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Andjelic B, Antic D, Jakovic L, Todorovic
M, Bogdanovic A, Djurasinovic V, Bila J and Mihaljevic B: A single
institution experience on 314 newly diagnosed advanced Hodgkin
lymphoma patients: The role of ABVD in daily practice. Eur J
Haematol. 93:392–399. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Suárez AL, Pulitzer M, Horwitz S,
Moskowitz A, Querfeld C and Myskowski PL: Primary cutaneous B-cell
lymphomas: Part I. Clinical features, diagnosis and classification.
J Am Acad Dermatol. 69(329): e1–e13; quiz 341–342. 2013.
|
13
|
White RM and Patterson JW: Cutaneous
involvement in Hodgkin's disease. Cancer. 55:1136–1145. 1985.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Tamaru J: Pathological diagnosis of
Hodgkin lymphoma. Nihon Rinsho. 72:450–455. 2014.(In Japanese).
PubMed/NCBI
|
15
|
Loo EY, Medeiros LJ, Aladily TN, Hoehn D,
Kanagal-Shamanna R, Young KH, Lin P, Bueso-Ramos CE, Manning JT Jr,
Patel K, et al: Classical Hodgkin lymphoma arising in the setting
of iatrogenic immunodeficiency: A clinicopathologic study of 10
cases. Am J Surg Pathol. 37:1290–1297. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Seymour JF: X. Extra-nodal lymphoma in
rare localisations: Bone, breast and testes. Hematol Oncol.
31(Suppl 1): S60–S63. 2013. View
Article : Google Scholar
|
17
|
Panico L, Tenneriello V, Ronconi F, Lepore
M, Cantore N, Dell'Angelo AC, Ferbo L and Ferrara F: High
CD20+ background cells predict a favorable outcome in
classical Hodgkin lymphoma and antagonize CD68+
macrophages. Leuk Lymphoma. 56:1636–1642. 2015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kamper P, Bendix K, Hamilton-Dutoit S,
Honoré B, Nyengaard JR and d'Amore F: Tumor-infiltrating
macrophages correlate with adverse prognosis and Epstein-Barr virus
status in classical Hodgkin's lymphoma. Haematologica. 96:269–276.
2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lister TA, Crowther D, Sutcliffe SB,
Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA and
Tubiana M: Report of a committee convened to discuss the evaluation
and staging of patients with Hodgkin's disease: Cotswolds meeting.
J Clin Oncol. 7:1630–1636. 1989.PubMed/NCBI
|
20
|
Yung L and Linch D: Hodgkin's lymphoma.
Lancet. 361:943–951. 2003. View Article : Google Scholar : PubMed/NCBI
|
21
|
Talpur R1, Venkatarajan S and Duvic M:
Mechlorethamine gel for the topical treatment of stage IA and IB
mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin
Pharmacol. 7:591–597. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Möbs M, Cerroni L, Flaig MJ, Lenze D,
Hummel M and Assaf C: Molecular diagnostics in cutaneous lymphomas.
J Dtsch Dermatol Ges. 4:25–35. 2013. View Article : Google Scholar
|
23
|
Jerusalem G, Beguin Y, Fassotte MF, Najjar
F, Paulus P, Rigo P and Fillet G: Whole-body positron emission
tomography using 18F-fluorodeoxyglucose compared to
standard procedures for staging patients with Hodgkin's disease.
Haematologica. 86:266–273. 2001.PubMed/NCBI
|
24
|
Jhanwar YS and Straus DJ: The role of PET
in lymphoma. J Nucl Med. 47:1326–1334. 2006.PubMed/NCBI
|
25
|
Connors JM, Klimo P, Adams G, Burns BF,
Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, et al:
Treatment of advanced Hodgkin's disease with
chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating
courses of MOPP and ABVD: A report from the National Cancer
Institute of Canada clinical trials group. J Clin Oncol.
15:1638–1645. 1997.PubMed/NCBI
|
26
|
Canellos GP, Anderson JR, Propert KJ,
Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A and
Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP,
ABVD, or MOPP alternating with ABVD. N Engl J Med. 327:1478–1484.
1992. View Article : Google Scholar : PubMed/NCBI
|